Understanding the knowledge, awareness, and attitudes of the public towards liver diseases in Malaysia.

"Conflicts of interest C.Y. is an employee of Gilead Sciences. S.S. was an employee of Cerner Enviza. For R.M., there are no conflicts of interest."

"The authors acknowledge Dr Vince Grillo of Cerner Enviza for his support in overseeing this research at all stages, along with Dr Amanda Woo for providing medical writing and editorial support and Ms Wilma Guo for providing biostatistical support. The authors also acknowledge the support from Kantar Profiles Network and its partners in the recruitment of the respondents in this study. This study was funded by Gilead Sciences, Hong Kong (funding/grant number: not available). Cerner Enviza received funding from Gilead Sciences for the conduct of the study and development of the manuscript. R.M. led and all authors (R.M., C.Y., and S.S.) contributed to the conceptualization or design, analyses, or interpretation of data, drafting of the article, and critical revision for important intellectual content. S.S. contributed to the execution, acquisition of data, and led manuscript writing. All authors (R.M., C.Y., and S.S.) contributed and provided input at the writing stage and the final draft. All authors have read and approved the final manuscript. This study is part of a regional liver index study conducted in Hong Kong, India, Indonesia, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam, and was administered centrally [21]. The protocol and questionnaire (#20-KANT-214) were submitted to the Pearl Institutional Review Board (Indianapolis, Indiana, USA) and were determined to be exempted for periods the data will be used in the study. This online survey is deemed non-interventional and online informed consent was obtained from all participants included in the study. The authors confirm that all relevant data are within the manuscript and its supporting information files."